MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202311047072 A) filed by Birla Institute Of Technology & Science, Pilani, Rajasthan, on Jan. 13, 2024, for 'drug eluting conjunctival device for the treatment of uveitis.'
Inventor(s) include Nirmal J; and Velmurugan K.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a drug-eluting conjunctival device for treating uveitis and other such inflammatory condition of the eye. The invention is based on the use of nanomicelles loaded into drug eluting conjunctival device to enhance the solubility of the drug apremilast. The invention also provides a methodology for preparing such drug-eluting conjunctival devices including preparing apremilast nanomicelles and master mold prepared using polydimethylsiloxane. The proposed conjunctival device is prepared by solvent casting and ultraviolet (UV) crosslinking techniques using 2-hydroxyethyl methacrylate as polymer along with UV crosslinking agents, ethylene glycol dimethacrylate (EGDMA) and diphenyl(2,4,6-trimethylbenzoyl) phosphine oxide (Photocure TPO). The conjunctival device of present invention has "crescent shape" which facilitates placing of the device in conjunctiva providing a prolonged drug retention and sustained drug release, thereby achieving the optimum drug concentration at target site. Based on various studies, the device is proven to be safe and non-irritant."
Disclaimer: Curated by HT Syndication.
